DK0682027T3 - Pyrrolopyrimidinderivater med antiproliferativ virkning - Google Patents

Pyrrolopyrimidinderivater med antiproliferativ virkning

Info

Publication number
DK0682027T3
DK0682027T3 DK95810271.7T DK95810271T DK0682027T3 DK 0682027 T3 DK0682027 T3 DK 0682027T3 DK 95810271 T DK95810271 T DK 95810271T DK 0682027 T3 DK0682027 T3 DK 0682027T3
Authority
DK
Denmark
Prior art keywords
protein
alkyl
substd
tyrosine
halo
Prior art date
Application number
DK95810271.7T
Other languages
English (en)
Inventor
Peter Dr Traxler
Pascal Dr Furet
Wolfgang K D Dr Brill
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of DK0682027T3 publication Critical patent/DK0682027T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK95810271.7T 1994-05-03 1995-04-25 Pyrrolopyrimidinderivater med antiproliferativ virkning DK0682027T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH138594 1994-05-03
CH24595 1995-01-30

Publications (1)

Publication Number Publication Date
DK0682027T3 true DK0682027T3 (da) 1998-05-04

Family

ID=25684008

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95810271.7T DK0682027T3 (da) 1994-05-03 1995-04-25 Pyrrolopyrimidinderivater med antiproliferativ virkning

Country Status (21)

Country Link
US (2) US5686457A (da)
EP (1) EP0682027B1 (da)
JP (1) JP3042760B2 (da)
KR (1) KR950031113A (da)
CN (1) CN1128263A (da)
AT (1) ATE159257T1 (da)
AU (1) AU695244B2 (da)
CA (1) CA2148324A1 (da)
CZ (1) CZ113195A3 (da)
DE (1) DE59500788D1 (da)
DK (1) DK0682027T3 (da)
ES (1) ES2109796T3 (da)
FI (1) FI952033A (da)
GR (1) GR3025158T3 (da)
HK (1) HK1002935A1 (da)
HU (1) HUT71818A (da)
IL (1) IL113531A0 (da)
NO (1) NO951684L (da)
NZ (1) NZ272031A (da)
PL (1) PL308426A1 (da)
SK (1) SK56195A3 (da)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0783505T3 (da) * 1994-09-29 2001-07-02 Novartis Ag Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
TW321649B (da) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69609602T2 (de) * 1995-04-03 2001-04-12 Novartis Ag Pyrazolderivate und verfahren zu deren herstellung
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
WO1996033977A1 (en) * 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
CA2224435C (en) * 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT888349E (pt) * 1996-01-23 2002-10-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
DK0938486T3 (da) * 1996-08-23 2008-07-07 Novartis Ag Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
ES2241146T3 (es) * 1997-08-05 2005-10-16 Pfizer Products Inc. 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido y.
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO1999051582A1 (fr) 1998-03-31 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques azotes
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AU763658B2 (en) 1998-06-02 2003-07-31 Osi Pharmaceuticals, Inc. Pyrrolo(2,3d)pyrimidine compositions and their use
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
CZ20004727A3 (cs) 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
ID28362A (id) * 1998-09-18 2001-05-17 Basf Ag 4-aminopirolopirimidina sebagai penghambat kinase
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
EP1669071B1 (en) * 1999-05-21 2009-07-22 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
PL204437B1 (pl) * 1999-05-21 2010-01-29 Bristol Myers Squibb Co Pochodna pirolotriazyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PL218519B1 (pl) 1999-12-10 2014-12-31 Pfizer Prod Inc Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7294633B2 (en) 2001-05-14 2007-11-13 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
CA2810339A1 (en) * 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
US6805491B2 (en) * 2002-05-20 2004-10-19 Stratos International, Inc. Stub having an optical fiber
WO2004007502A1 (en) * 2002-07-11 2004-01-22 Bayer Pharmaceuticals Corporation Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders
MXPA05005576A (es) 2002-11-26 2005-07-27 Pfizer Prod Inc Procedimiento de tratamiento del rechazo a un trasplante.
WO2004093812A2 (en) * 2003-04-22 2004-11-04 Irm Llc Compounds that induce neuronal differentiation in embryonic stem cells
DE602004003952T2 (de) * 2003-07-24 2007-11-08 Bayer Pharmaceuticals Corp., West Haven Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005084401A2 (en) * 2004-03-02 2005-09-15 Neurogen Corporation Aryl substituted purine analogues
AU2005230818B2 (en) * 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
WO2006136402A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
EP2004656B1 (en) 2006-04-07 2013-07-10 Boehringer Ingelheim International GmbH Thienopyrimidines having mnk1 /mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
SI2384326T1 (sl) 2008-08-20 2014-06-30 Zoetis Llc Pirolo(2,3-d)pirimidinske spojine
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
BR112012021453A2 (pt) 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
BR112012021364A2 (pt) 2010-02-26 2016-10-25 Boehringer Ingelheim Int "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CN103582643B (zh) * 2011-04-04 2016-06-15 弗马塞斯有限公司 蛋白激酶抑制剂
CA2760174A1 (en) * 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN104024432B (zh) 2011-08-31 2017-02-22 基因泰克公司 诊断性标志物
US20130084287A1 (en) 2011-09-30 2013-04-04 Genentech, Inc. Diagnostic markers
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2015518842A (ja) * 2012-05-21 2015-07-06 バイエル ファーマ アクチエンゲゼルシャフト 置換ピロロピリミジン
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
ES2637245T3 (es) 2012-06-29 2017-10-11 Pfizer Inc. Nuevas 4-(amino sustituido)-7H-pirrolo[2,3-d]pirimidinas como inhibidores de LRRK2
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
MX2017008421A (es) 2014-12-24 2018-03-23 Genentech Inc Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
BR112019012976A2 (pt) 2016-12-22 2019-12-31 Amgen Inc inibidores de kras g12c e métodos de uso dos mesmos
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3788053A1 (en) 2018-05-04 2021-03-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7361720B2 (ja) 2018-05-10 2023-10-16 アムジエン・インコーポレーテツド がんの治療のためのｋｒａｓ ｇ１２ｃ阻害剤
JP7268264B2 (ja) 2018-05-11 2023-05-08 慶應義塾 ピロロピリミジン化合物を有効成分とする炎症性疾患の予防及び／又は治療剤
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
MA55136A (fr) 2018-11-19 2022-02-23 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
JOP20210154B1 (ar) 2018-12-20 2023-09-17 Amgen Inc مثبطات kif18a
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sólido
CN114391012A (zh) 2019-08-02 2022-04-22 美国安进公司 作为kif18a抑制剂的吡啶衍生物
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
JP2022542319A (ja) 2019-08-02 2022-09-30 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
EP4048671A1 (en) 2019-10-24 2022-08-31 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
MX2022005360A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN116425742A (zh) 2019-11-08 2023-07-14 锐新医药公司 双环杂芳基化合物及其用途
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4087611A1 (en) 2020-01-07 2022-11-16 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
EP4168002A1 (en) 2020-06-18 2023-04-26 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
CN117683049A (zh) 2020-09-15 2024-03-12 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
US20230106174A1 (en) 2021-05-05 2023-04-06 Revolution Medicines, Inc. Ras inhibitors
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915304A (en) * 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives
GB980515A (en) * 1962-03-01 1965-01-13 Wellcome Found 7-substituted pyrrolo[2,3-d]pyrimidines
US3311628A (en) * 1965-03-09 1967-03-28 Bristol Myers Co Derivatives of pyrrolo [2, 3-d] pyrimidine
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
DE2818676A1 (de) 1978-04-27 1979-11-08 Troponwerke Gmbh & Co Kg Substituierte 5,6-dimethylpyrrolo 2,3-d pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
JPS63107966A (ja) * 1986-05-22 1988-05-12 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体
US5256650A (en) * 1989-03-29 1993-10-26 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
JPH03107966A (ja) * 1989-09-22 1991-05-08 Ricoh Co Ltd 現像装置
CA2032695A1 (en) * 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
CA2051012C (en) * 1990-09-14 2002-04-02 David R. Borcherding Carbocyclic adenosine analogs useful as immunosupressants
JPH04141649A (ja) * 1990-10-02 1992-05-15 Konica Corp 塩化銀を含む８面体、１４面体粒子乳剤の製造方法
ATE159009T1 (de) * 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE4230262A1 (de) * 1992-09-10 1994-03-17 Behringwerke Ag Substituierte Phenole, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von zellproliferationsbedingten Erkrankungen
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5543413A (en) * 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
DK0783505T3 (da) * 1994-09-29 2001-07-02 Novartis Ag Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
DK0831829T3 (da) * 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
CA2224435C (en) * 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof

Also Published As

Publication number Publication date
CA2148324A1 (en) 1995-11-04
HU9501230D0 (en) 1995-06-28
ES2109796T3 (es) 1998-01-16
JP3042760B2 (ja) 2000-05-22
HK1002935A1 (en) 1998-09-25
DE59500788D1 (de) 1997-11-20
US6096749A (en) 2000-08-01
AU1772295A (en) 1995-11-09
IL113531A0 (en) 1995-07-31
FI952033A0 (fi) 1995-04-28
HUT71818A (en) 1996-02-28
PL308426A1 (en) 1995-11-13
NO951684D0 (no) 1995-05-02
SK56195A3 (en) 1996-05-08
NO951684L (no) 1995-11-06
EP0682027B1 (de) 1997-10-15
KR950031113A (ko) 1995-12-18
NZ272031A (en) 1997-01-29
EP0682027A1 (de) 1995-11-15
CN1128263A (zh) 1996-08-07
AU695244B2 (en) 1998-08-13
JPH0853454A (ja) 1996-02-27
GR3025158T3 (en) 1998-02-27
CZ113195A3 (en) 1995-12-13
US5686457A (en) 1997-11-11
ATE159257T1 (de) 1997-11-15
FI952033A (fi) 1995-11-04

Similar Documents

Publication Publication Date Title
DK0682027T3 (da) Pyrrolopyrimidinderivater med antiproliferativ virkning
ES8506020A1 (es) Procedimiento para preparar derivados de 4-oxo-1, 4-dihidroquinoleina
AU3564395A (en) Pyrrolo(2,3-d)pyrimidines and their use
NZ337121A (en) Pyrazine compounds as good anti-convulsants for the treatment of CNS diseases such as epilepsy
ATE42037T1 (de) Porphyrine und krebsbehandlung.
MY112110A (en) Novel 1,2,4-triazolo [1,5 a] pyrimidine compounds, their pharmaceutical compositions and use in the treatment of neurological disorders,and processes for their preparation.
DK374085D0 (da) Tryptamin-derivater, deres fremstilling og anvendelse som laegemidler
ES2111616T3 (es) Compuestos de ciclohexapeptidil bisamina.
ES533653A0 (es) Procedimiento para preparar pirazol(aril)metanonas
DK310785D0 (da) Ringkondenserede pyrazolo(3,4-d)-pyridin-3-oner og salte deraf samt deres fremstilling og anvendelse
ATE88176T1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
AU1815092A (en) Intermediates used in preparation of pyrrolo{1,2-a}-imidazole and pyrrolo{1,2-a}pyridine derivatives
ES2195996T3 (es) Compuestos de hidroxipropionitrilo ciclohexapeptidilo.
FR2267102A1 (en) 2,6-Di(branched alkylamino)pyridines - for treatment of fatty degeneration and diabetes
FI963808A (fi) Menetelmä (1H-tetratsol-5-yyli)tetratsolo(1,5-a)kinoliinien ja naftyridiinien valmistamiseksi
ES8604591A1 (es) Procedimiento para preparar nuevas 11-piperazinil-5h-imidazo(2,1-c)(1,4)-benzodiazepinas
MY101822A (en) (5r,6s,8r)-6-(1-hydroxyethyl)-2-(3r-pyrrolidin-2-one-3-yl-)thiopenem-3-carboxylic acid.
AU2427188A (en) Enhancing drug delivery to the brain
ES8600767A1 (es) Un procedimiento para la preparacion de derivados de 7-oxo-1-azabiciclo (3.2.0) hepteno
JO1785B1 (en) Therapeutic agents
ES8604875A1 (es) Procedimiento para la obtencion de derivados de pirrolpropionitrilo

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment